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Abstract
Aim. The purpose of our study was to develop a method for simultaneous quantitation of voglibose and quercetin in a solid 
dosage form.
Materials and methods. The objects of the study were voglibose, quercetin, tablets containing voglibose – 0.2 mg 
and quercetin 100 mg. Measurements were carried out by high-performance liquid chromatography (HPLC) according to 
SPHU, supp. 1, 2.2.29, N, using the following equipment: a mass-selective detector Agilent 6530 Q-TOF was used as the de- 
tecting system.
Results. According to the developed method, the quantitative determination of voglibose and quercetin in the tablets of 
hypoglycaemic action was investigated. The following results were obtained: the content of C 10 H 21 NO 7 (voglibose) in one 
dosage unit of the test drug was 0.2 mg; and the content of C 15 H 10 O 7 (quercetin) - 0.105 g, which suggests the validability 
of the proposed method for quantitation of the active substances in tablets for the prevention and treatment of type II diabetes 
mellitus.
Conclusions. In the course of the study, a method was developed for determination of voglibose and quercetin in a hypo-
glycaemic action preparation using high-performance liquid chromatography (HPLC) with a gradient mode of elution. It has been 
established that the chosen chromatographic conditions allow quantitative determination of the active pharmaceutical ingredients 
studied in a solid dosage form with a tolerance of ±5 %. Validation of the developed methodology has been conducted and its suit-
ability for the simultaneous quantification of quercetin and voglibose in tablets has been demonstrated. The reproducibility of this 
method has been proved.
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1. Introduction
Today, diabetes mellitus (DM) is one of the leading medical and social problems that is rap-
idly gaining momentum: more than 300 million people worldwide suffer this disease [1]. According 
to the forecasts of the World Health Organization, by 2035 the number of patients with diabetes will 
increase to 592 million [2]. In Ukraine, according to statistics, the number of patients with diabetes 
at the beginning of 2018 was 104 thousand, but the real indicator of this pathology incidence is 
almost 2 times higher [3].
It is proved that monotherapy of type II DM with only one of oral hypoglycaemic drugs 
has positive results only in the first 5–6 years of the disease, in the future there is a need for the 
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combination therapy with drugs from different groups [4]. Therefore, one of the promising di-
rections is the development of combined drugs with various mechanisms of hypoglycemic and 
prophylactic action in relation to secondary complications with satisfactory biopharmaceutical 
characteristics [5]. As active pharmaceutical ingredients (APIs), according to the pharmaco-
logical studies, it is suggested to use a combination of voglibose and quercetin [6].
Quercetin has powerful antioxidant properties [7]. It is proved that it inhibits processes 
of not only non-enzyme but also enzymatic lipid peroxidation (LPO) [8], but also protects from 
oxidation ascorbic acid and adrenaline, whose oxidation products can further activate LPO [9]. 
It has also been established that quercetin preparations contribute to the reduction of patho-
logical manifestations in type II diabetes, which is accompanied by obesity: hyperglycemia, 
hyperlipidemia, imbalance in the system of interleukins and nitric oxide in both serum and 
myocardium [10]. However, its long application is limited due to low solubility [11].
Voglibose belongs to the group of hypoglycaemic agents, which are included in the Unified 
clinical protocol of primary and secondary (specialized) medical aid in case of type 2 diabetes mel-
litus, approved by the Ministry of Health of Ukraine dated December 21, 2012, Order No. 1118 [12].
The principle of voglibose action is based on the competitive inhibition of enzymes and a decrease 
in the rate of glucose release from complex carbohydrates, which leads to a decrease in postpran-
dial hyperglycaemia and a decrease in the level of oxidative stress and inflammatory markers in 
patients with DM [13]. Voglibose effectively improves glycemic control and helps reduce glyco-
sylated haemoglobin by an average of 2 % without any side effects on weight gain [14]. It was 
established that the use of voglibose is effective in preventing the occurrence of type II diabetes in 
people with impaired glucose tolerance [15].
It is known that quantitation of APIs in combined medicines is one of the most difficult tasks 
of pharmaceutical development.
2. Aim of research
Develop a method for simultaneous quantitation of voglibose and quercetin in a solid 
dosage form.
3. Materials and methods
Investigations were carried out in the State scientific-research laboratory of NUPh for me-
dicinal substances quality control in 2018.
The objects of the study were voglibose, quercetin, tablets containing voglibose – 0.2 mg 
and quercetin 100 mg.
Measurements were carried out by high-performance liquid chromatography (HPLC) ac-
cording to SPHU, supp .1, 2.2.29, N [16], using the following equipment: a mass-selective detector 
Agilent 6530 Q-TOF was used as the detecting system. This detector was used in conjunction 
with a liquid chromatograph Agilent 1290 equipped with a diode matrix, a four-channel pump for 
forming a low-pressure gradient, an automatic sampler and a thermostat of columns. Mass Hunter 
B04.01 software was used to process the measured results [16]. In addition to the above equipment 
to conduct research used:
– Electronic laboratory balance ABT 120-5DM
– Starter ST2100 pH meter by Ohaus.
– Measuring glassware of the accuracy class A in the required quantity.
Equipment with metrological certification was used according to the approved standard 
working method (SWM).
In the following conditions, total ion current chromatograms were obtained for test solutions.
Method of quantitation.
The contents of voglibose and quercetin (X), in mg, in a tablet, were calculated by the formula:
i 0
0 i
S m 100 b P 1000
x ,
S m 500 100
× × × × ×
=
× × ×
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where Si is the mean value of the peak area of voglibose or quercetin, which is calculated from the 
chromatograms of the test solution; S0 – average value of peak area of voglibose or quercetin, which 
is calculated from the chromatograms of the comparison solution; m0 – the weight of the standard 
sample of voglibose or quercetin CRS, in milligrams; mi – weight of drug sample, in milligrams; 
P – the content of voglibose or quercetin in the standard CRS sample of the tablet, as a percentage; 
b – average weight of the tablet, mg.
The content of C10H21NO7 (voglibose) in one dosage unit of the test drug should be from 
0.18 mg to 0.22 g.
The content of C15H10O7 (quercetin) in a single dosage unit of the test drug should be from 
0.9 to 0.11 g.
Measurements were carried out by liquid chromatography. Approximately 600 mg (exact 
weighting), of the mass of 10 grounded pills placed in a 100 ml volumetric flask, 50 ml of methanol 
P was added and placed on an ultrasound bath for 20 minutes. The solution was cooled; the volume 
of solution was added with methanol P to the label and stirred for 10 minutes. The solution was 
filtered through a 0.45 μm PTFE filter (test solution).
The comparison solution was chromatographed, obtaining from 2 to 6 chromatograms. In-
jection volume was 80 μl. Relative standard deviation (RSD) was calculated for areas of voglibose 
and quercetin peaks on obtained chromatograms.
Obtaining of parallel chromatograms (n0) was terminated when the requirements for (RSD) 
specified in SPHU 2.2.46, N, Table 2.2.46-2 were met.
The solution to be tested and the comparison solution were chromatographed alternately; 
obtaining the number of parallel chromatograms (n) for each solution is not less than that for check-
ing the suitability of the chromatographic system under the following conditions:
– a column of 250×4.0 mm which is filled with a octosilicagel-bonded sorbent (L7), a parti-
cle size of 5 μm XTerra MS C8 (Waters) or a similar one for which the requirements of the section 
“The suitability of the chromatographic system” are met;
– flow rate – 1 ml/min;
– temperature of the thermostat of the column – 30 oС;
– mobile phase A: 0.005M solution of ammonium formiate in water P degassed in any con-
venient way;
– mobile phase B: 0,005M solution of ammonium formiate in the mixture of acetonitrile 
P – water P (90:10) degassed in any convenient way;
– elution mode – isocratic;
– the ratio of the mobile phase A to the mobile phase B should be as 40:60;
– volume of injection 5 μl;
– detector – mass spectrometer (Agilent 6420 Triple Quad);
– detector settings:
– type of ionization: positive, electric spray (+ESI);
– mode of measurement: the accumulation of ions with a mass of 268 and 302 AU.;
– voltage at fragmentor 50 V;
– temperature of nitrogen 350 oС;
– nitrogen consumption 10 ml/min;
– pressure on the nebuliser 35 PSI;
– voltage at capillary 4 kV.
The results of the analysis were considered reliable if the requirements of the test “Checking 
the suitability of the chromatographic system” were met.
Note. Preparation of the solution for comparison. 5 mg of voglibose and 50 mg of quercetin 
CRS were placed in a 500 ml volumetric flask, 400 ml of methanol P were added and placed on an 
ultrasound bath until complete dissolution. The solution was cooled, the volume of solution was 
added with methanol P to the mark and stirred. The solution was used freshly prepared.
Checking the suitability of the chromatographic system.
The chromatographic system was considered suitable if the following conditions were met:
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– the efficiency of the chromatographic column, calculated from the peak of voglibose and 
quercetin on the chromatogram of the comparison solution, should be at least 1000 theoretical 
plates (SPHU);
– the peak asymmetry coefficient, calculated for the peak of voglibose and quercetin on the 
chromatogram of the comparison solution, should be no more than 2.0 (SPHU).
4. Research results
The uncertainty of voglibose and quercetin content in one tablet should not exceed ±5 %, 
which allows calculating the maximum uncertainty of the method of quantitation ΔA s=1.6 % [17]. 
Based on these requirements, the validation of the developed technique has been carried out and 
its suitability for simultaneous quantitation of both voglibose and quercetin in medicinal form 
was proved. Before carrying out of the basic validation tests, the presence of documents proving 
the suitability of the used equipment, raw materials and reagents was controlled. Validation of the 
methodology was carried out in accordance with the requirements of the State Pharmacopoeia of 
Ukraine [14].
In the above conditions, the chromatograms of the test solution and the comparison solution 
were obtained (Fig. 1, 2).
a
b
Fig. 1. Voglibose chromatogram: a – the comparison solution; b – the test solution
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Since the method of high-performance liquid chromatography is specific, to prove it is 
enough to meet all the requirements for the criteria for linearity, repeatability, precision, accuracy 
and intermediate precision.
a  
b
Fig. 2. Chromatogram of quercetin: a –the comparison solution; b –the test solution
The linearity evaluation was carried out over the entire range of application of the meth-
odology by the standard method. The study of the nature of the optical density dependence on the 
concentration was carried out using 9 model solutions for analysis with concentrations: 80, 85, 90, 
95, 100, 105, 110, 115 and 120 %. The results of the linear dependence of the peak area on the con-
centration of voglibose and quercetin are shown in Fig. 3, 4, respectively. Characteristics of linear 
dependence for voglibose and quercetin are presented in Table 1, 2.
In both cases, the linearity requirements are met.
For measuring and calculating the metrological assessment of the repeatability and accuracy 
of the methodology, three values of peak areas for the comparison solution and 27 values of peak 
areas for model solutions were obtained. Calculated actual value (Xifact), the ratio of average values 
of peak areas for each of the 27 solutions to the mean peak area of reference solution by getting the 
value of Xi=(Ci/CSt)×100 %, Yi=(Si/Sst)×100 %, as well as the value of Zi=(Yi/Xi)×100 %, which is 
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the ratio of found concentration over the introduced in percents. The results of calculations for the 
investigated APIs are shown in Table 3, 4.
Fig. 3. Linear dependence of the peak area on the concentration of voglibose in normalized 
coordinates
Fig. 4. Linear dependence of peak area on the concentration of quercetin in normalized 
coordinates
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Table 1
Characteristics of linear dependence for voglibose
Parameters Value Requirement 1 Requirement 2 Conclusion
b 0.99864235
Sb 0.0020435845
a |0.045855281| <=|0.38284396| <=|2.528| the first criterion are respected
Sa 0.20588543
RSD0 0.079147686
RSD0 /b |0.079255287| <=|0.86044636| are maintained
RSD
y
12.909944
r |0.99998121| >|0.99777642 | are maintained
Note: Student (95, 1, 8)=1.8595, r – the relative retention of the component, RSD (%) – relative standard deviation, b – the angle of 
inclination, a – free member straight, S – the tangent of the angle of the calibration curve
Table 2
Characteristics of linear dependence for quercetin
Parameters Value Requirement 1 Requirement 2 Conclusion
b 1.0026694
Sb 0.0024905942
a |–0.19287495| <=|0.4665865| <=|2.528| the first criterion are respected
Sa 0.25092041
RSD0 0.096460298
RSD0 /b |0.096203492| <=|0.86044636| are maintained
RSD
y
12.909944
r |0.99997209| >|0.99777642| are maintained
Note: Student (95, 1, 8)=1.8595.
Table 3
Results of analysis of model solutions of voglibose and their statistical processing
Solutions Name Medium Si Ci Sir Cir di
1 RS 16578534 100 100 100 100
2 M1 13243263 80 79.881988 80 99.852485
3 M2 14062795 85 84.825323 85 99.794498
4 M3 14920395 90 89.998274 90 99.998083
5 M4 15750280 95 95.004055 95 100.00427
6 M5 16556170 100 99.8651 100 99.8651
7 M6 17405127 105 104.98592 105 99.986591
8 M7 18210479 110 109.84372 110 99.857927
9 M8 19042474 115 114.86223 115 99.880198
10 M9 19866770 120 119.8343 120 99.861913
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Table 4
Results of analysis of model solutions of quercetin and their statistical processing
Solutions Name Medium Si Ci Sir Cir d i
1 RS 1524874 100 100 100 100
2 M1 1221600.5 80 80.11157 80 100.13946
3 M2 1297765.5 85 85.106409 85 100.12519
4 M3 1372048.5 90 89.977828 90 99.975364
5 M4 1447766.5 95 94.943353 95 99.940371
6 M5 1526486.5 100 100.10575 100 100.10575
7 M6 1603155 105 105.1336 105 100.12724
8 M7 1676719.5 110 109.9579 110 99.961732
9 M8 1756670.5 115 115.20103 115 100.17481
10 M9 1832947.5 120 120.20321 120 100.16934
5. Discussion of the research results
The obtained results of voglibose and quercetin quantitation in the preparation developed 
according to the given method testify to its reproducibility.
Validation of voglibose and quercetin quantitation method was carried out according to 
individual validation characteristics: specificity, linearity, repeatability, precision, accuracy and 
intermediate precision.
In order to estimate the sampling error of the model solutions and the comparison solution, 
the theoretical values of the uncertainty of the analytical operation were calculated, which was 
Δsp=0.5 %.
During the validation it was proved that sample preparation slightly affects the result of the 
quantitative determination, so it was not analysed [18].
The obtained results were statistically processed by the method of least squares in accor-
dance with the requirements of the SPHU.
Requirements for linear dependency parameters are met throughout the range of application 
of the technique (80–120 %).
For the estimation of intermediate precision, a relative confidence interval for 5 parallel 
determinations of the substances’ quantitative content was used, which should be less than the 
maximum uncertainty of the results of the analysis: Δz≤1.6 %. The tests were performed using 
one series of the drug with different analysts on a single chromatograph on different days using 
different measuring glassware.
Intermediate precision was confirmed by the fact that the value of the relative confidence 
interval for five parallel determinations of one series of the drug meets the eligibility criterion.
According to the developed method, the quantitative determination of voglibose and quercetin 
in the tablets of hypoglycaemic action was investigated [19]. The following results were obtained: the 
content of C10H21NO7 (voglibose) in one dosage unit of the test drug was 0.2 mg; and the content of 
C15H10O7 (quercetin) – 0.105 g, which suggests the validity of the proposed method for quantitation 
of the active substances in tablets for the prevention and treatment of type II diabetes mellitus [20].
6. Conclusions
1. In the course of the study, a method was developed for determination of voglibose and 
quercetin in a hypoglycaemic action preparation using high-performance liquid chromatography 
(HPLC) with a gradient mode of elution
2. It has been established that the chromatographic conditions chosen allow quantitative 
determination of the active pharmaceutical ingredients studied in a solid dosage form with a toler-
ance of ±5 %.
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3. Validation of the developed methodology has been conducted and its suitability for the 
simultaneous quantification of quercetin and voglibose in tablets has been demonstrated. The re-
producibility of this method has been proved.
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